HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 10 June 2013

Recents CEAs

Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers.  23 papers were listed this time. Here's a few in our areas of research interest:

Cammà C, Petta S, Cabibbo G, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol. 2013 May 23. [Epub ahead of print] PubMed PMID: 23707373.

Chan K, Lai MN, Groessl EJ, et al. Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration. Clin Gastroenterol Hepatol. 2013 May 22 [Epub ahead of print] PubMed PMID: 23707354.

Bartsch SM, Umscheid CA, Fishman N, et al. Is Fidaxomicin worth the cost? An economic analysis. Clin Infect Dis. 2013 May 23. [Epub ahead of print] PubMed PMID: 23704121.

Holt S, Bertelli G, Humphreys I, et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK. Br J Cancer. 2013 May 21. [Epub ahead of print] PubMed PMID: 23695023.